Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-γδT Cells for CD7+ T-Cell Malignancies
NCT04702841Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA07 in t-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma, sponsored by PersonGen BioTherapeutics. Primary endpoint: Objective Response Rate at 3 months. Status: unknown.
02
Drugs
UTAA07
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoma
Beyond the preview
Go deeper on NCT04702841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702841.